Several years ago the European and American drug regulation authorities (EMA and FDA) set up a fast-track approval system for orphan drugs, unlike Japan. To enable Japanese legislation to develop along the same lines, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has just completed an EMA training programme on orphan medicines and rare diseases – which now affect approximately 180,000 people as against 50,000 previously.
